Email: globalhealth@lancet.com Covering letter • You should upload your covering letter at the “Enter Comments” stage of the online submission process • Use the covering letter to explain why your paper should be published in The Lancet Global Health rather than elsewhere Statements, permiss...
The Lancet is an independent and authoritative voice in global medicine. We seek to publish high-quality clinical trials that will alter medical practice; our commitment to international health ensures that research and analysis from all regions of the world...
Submission to acceptance EditorialOpen access Fixing the system to end violence against women The Lancet Global Health November 2024View PDF DiscussionOpen access Maternal intimate partner violence and child health outcomes Rachel Jewkes, Mercilene Machisa ...
2014年9月初,柳叶刀The Lancet发布了新的杂志The Lancet HIV,加上去年发布的的杂志Lancet Global Health,柳叶刀期刊列表增加到了10个,从这节奏看来柳叶刀打算做期刊方阵啊。 About The Lancet HIV About the journal The Lancet HIV launches in autumn 2014, joining the growing collection of Lancet specialty jour...
拒稿信应该是模板如下:Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one,...
The Lancet Public Health is a online-only, open access title in The Lancet's growing family of specialty journals. Building on the foundation of The Lancet as a champion of public health research, this monthly journal is committed to publishing high-quality original Research Articles, Editorials,...
The journal fosters the advance of clinical practice and health policy in the Americas, with the ultimate goal of … View full aims & scope $4480 Article publishing charge for open access 6 days Time to first decision 49 days Review time 128 days Submission to acceptance View all insights...
拒稿信应该是模板如下:Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one,...
sales in each calendar year (20% up to USD 500 million, 30% from USD 500 million up to USD 2.0 billion, and 35% above USD 2.0 billion) for the licensed products in the collaboration indications. Janssen Biotech, Inc. will oversee the Phase 3 development and submission for any additional...
The journal fosters the advance of clinical practice and health policy in the European region, with the goal of … View full aims & scope $4480 Article publishing charge for open access 2 days Time to first decision 27 days Review time 65 days Submission to acceptance View all insights...